Cargando…
Visual acuity and electroretinography findings 3 ½ years after the first intravitreal injection of bevacizumab (Avastin) in aggressive posterior retinopathy of prematurity
Autores principales: | Shah, Parag K, Morris, Rodney J, Narendran, V, Kalpana, N |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3032257/ https://www.ncbi.nlm.nih.gov/pubmed/21157086 http://dx.doi.org/10.4103/0301-4738.73707 |
Ejemplares similares
-
Intravitreal bevacizumab (Avastin) for the treatment of proliferative sickle retinopathy
por: Shaikh, Saad
Publicado: (2008) -
Intravitreal Bevacizumab (Avastin) as an Adjuvant for the Treatment of Posterior Scleritis
por: Lim, Ji Won, et al.
Publicado: (2011) -
Intravitreal Bevacizumab (Avastin) for Diabetic Retinopathy: The 2010 GLADAOF Lecture
por: Arevalo, J. Fernando, et al.
Publicado: (2011) -
Aggressive Posterior Retinopathy of Prematurity: Long-Term Outcomes Following Intravitreal Bevacizumab
por: Naravane, Ameay V., et al.
Publicado: (2022) -
Impact of Intravitreal Injection of Bevacizumab (Avastin) on Rabbit's Choroid and Retina
por: Karawya, Sherif, et al.
Publicado: (2008)